Anteris technologies and v2vmedtech announce concept lock of next generation mitral and tricuspid repair system as vclip™ passes animal study

Brisbane, australia & eagan, minn.--(business wire)--anteris technologies ltd (asx: avr), a structural heart company developing duravr™ thv, a new class of tavr and the world's only balloon-expandable, single-piece biomimetic aortic replacement valve shaped to mimic the native human valve, and v2vmedtech, inc., a structural heart company developing a next generation transcatheter edge to edge repair (teer) system for mitral and tricuspid valve regurgitation today announced they have reached con.
AVR Ratings Summary
AVR Quant Ranking